Michael Houghton
#4,781
Most Influential Person Now
Virologist
Michael Houghton 's AcademicInfluence.com Rankings
Michael Houghton biology Degrees
Biology
#588
World Rank
#1040
Historical Rank
Virology
#44
World Rank
#46
Historical Rank
Download Badge
Biology
Michael Houghton 's Degrees
- PhD Virology King's College London
- Bachelors Biological Sciences University of East Anglia
Why Is Michael Houghton Influential?
(Suggest an Edit or Addition)Michael Houghton 's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. (1989) (6986)
- Binding of hepatitis C virus to CD81. (1998) (2166)
- Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. (1989) (1655)
- A proposed system for the nomenclature of hepatitis C viral genotypes (1994) (1100)
- HEPATITIS C VIRUS ANTIBODIES AMONG RISK GROUPS IN SPAIN (1989) (907)
- Molecular biology of the hepatitis C viruses: Implications for diagnosis, development and control of viral disease (1991) (892)
- Analysis of a successful immune response against hepatitis C virus. (1999) (891)
- Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. (1996) (722)
- Detection of hepatitis C viral sequences in non-A, non-B hepatitis (1990) (687)
- PREVALENCE OF ANTIBODIES TO HEPATITIS C VIRUS IN ITALIAN PATIENTS WITH HEPATOCELLULAR CARCINOMA (1989) (673)
- Memory CD8+ T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection (2003) (667)
- Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. (1991) (651)
- Structure, sequence and expression of the hepatitis delta (δ) viral genome (1986) (541)
- Confirmation of hepatitis C virus infection by new four-antigen recombinant immunoblot assay (1991) (504)
- Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. (1992) (500)
- Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5' untranslated region and poly(A) tails at the 3' end. (1991) (445)
- The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. (2001) (439)
- Recurrence of hepatitis C virus after loss of virus specific CD4+ T cell response in acute hepatitis C (1998) (439)
- Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. (1990) (400)
- Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. (1995) (387)
- A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. (1996) (381)
- Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. (1995) (363)
- HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. (1995) (350)
- The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. (1997) (333)
- Prospects for a vaccine against the hepatitis C virus (2005) (328)
- Immunodominant CD4+ T-cell epitope within nonstructural protein 3 in acute hepatitis C virus infection (1997) (324)
- Hepatitis C virus (HCV)-specific cytotoxic T lymphocytes recognize epitopes in the core and envelope proteins of HCV (1993) (320)
- Quantitative analysis of the peripheral blood cytotoxic T lymphocyte response in patients with chronic hepatitis C virus infection. (1996) (317)
- ANTI-HEPATITIS C ANTIBODIES AND NON-A, NON-B POST-TRANSFUSION HEPATITIS IN THE NETHERLANDS (1989) (313)
- Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients (1996) (283)
- Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. (2005) (272)
- Hepatitis C virus antibodies in southern African blacks with hepatocellular carcinoma (1990) (268)
- Compartmentalization of T lymphocytes to the site of disease: intrahepatic CD4+ T cells specific for the protein NS4 of hepatitis C virus in patients with chronic hepatitis C (1993) (260)
- Structure-Function Analysis of Hepatitis C Virus Envelope-CD81 Binding (2000) (254)
- Epidemiology of hepatitis C virus. A preliminary study in volunteer blood donors. (1990) (250)
- Hepatitis C antibody and chronic liver disease in haemophilia (1990) (245)
- Protective immune response to hepatitis C virus in chimpanzees rechallenged following clearance of primary infection (2001) (244)
- Characterization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia viruses (1993) (241)
- A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan (1991) (237)
- Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. (2010) (236)
- Hepatitis C–associated hepatocellular carcinoma (1990) (228)
- Expression, identification and subcellular localization of the proteins encoded by the hepatitis C viral genome. (1993) (225)
- A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 delta and p27 delta (1988) (222)
- Liver-derived CTL in hepatitis C virus infection: breadth and specificity of responses in a cohort of persons with chronic infection. (1998) (202)
- The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor. (1993) (200)
- Association of hepatitis C virus envelope proteins with exosomes (2004) (194)
- Vertical transmission of hepatitis C virus (1991) (188)
- The way forward in HCV treatment — finding the right path (2008) (187)
- Detection of antibody against antigen expressed by molecularly cloned hepatitis C virus cDNA: application to diagnosis and blood screening for posttransfusion hepatitis. (1990) (179)
- Heterocyst Pattern Formation Controlled by a Diffusible Peptide (1998) (177)
- Early events in hepatitis C virus infection of chimpanzees. (1990) (169)
- Long‐term follow‐up of patients with chronic hepatitis C treated with different doses of interferon‐α2b (1993) (163)
- Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses (2011) (162)
- A Hepatitis C Virus (HCV) Vaccine Comprising Envelope Glycoproteins gpE1/gpE2 Derived from a Single Isolate Elicits Broad Cross-Genotype Neutralizing Antibodies in Humans (2013) (161)
- Hepatitis C virus antigen in hepatocytes: immunomorphologic detection and identification. (1992) (160)
- Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. (1997) (159)
- The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. (1991) (159)
- Association of multispecific CD4(+) response to hepatitis C and severity of recurrence after liver transplantation. (1998) (158)
- Antibody response to core, envelope and nonstructural hepatitis C virus antigens: Comparison of immunocompetent and immunosuppressed patients (1993) (153)
- Immune responses to plasmid DNA encoding the hepatitis C virus core protein (1995) (151)
- Storage conditions of blood samples and primer selection affect the yield of cDNA polymerase chain reaction products of hepatitis C virus (1992) (150)
- Complex processing and protein:protein interactions in the E2:NS2 region of HCV. (1994) (150)
- Hepatitis C virus core and E2 protein expression in transgenic mice (1997) (150)
- A cDNA fragment of hepatitis C virus isolated from an implicated donor of post-transfusion non-A, non-B hepatitis in Japan. (1989) (149)
- A unique, predominant hepatitis C virus variant found in an infant born to a mother with multiple variants (1993) (148)
- The putative nucleocapsid and envelope protein genes of hepatitis C virus determined by comparison of the nucleotide sequences of two isolates derived from an experimentally infected chimpanzee and healthy human carriers. (1990) (147)
- The long and winding road leading to the identification of the hepatitis C virus. (2009) (147)
- High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C (1998) (147)
- The impact of the interferon-lambda family on the innate and adaptive immune response to viral infections (2014) (141)
- Use of a signature nucleotide sequence of hepatitis C virus for detection of viral RNA in human serum and plasma (1991) (135)
- Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. (1993) (133)
- Small Interfering RNA-Mediated Inhibition of Hepatitis C Virus Replication in the Human Hepatoma Cell Line Huh-7 (2003) (128)
- Synthesis and Characterization of a Native, Oligomeric Form of Recombinant Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein (2004) (127)
- Structure, sequence and expression of the hepatitis delta (delta) viral genome. (1986) (127)
- The way forward in HCV treatment — finding the right path (2007) (127)
- Transfection of a differentiated human hepatoma cell line (Huh7) with in vitro-transcribed hepatitis C virus (HCV) RNA and establishment of a long-term culture persistently infected with HCV (1995) (122)
- Activation of the grp78 andgrp94 Promoters by Hepatitis C Virus E2 Envelope Protein (1999) (119)
- Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies. (2018) (117)
- Discovery of the hepatitis C virus (2009) (114)
- Structure, sequence and expression of the hepatitis delta (δ) viral genome (1987) (112)
- Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers (2009) (109)
- Human CD4+ T-cell response to hepatitis delta virus: identification of multiple epitopes and characterization of T-helper cytokine profiles (1997) (108)
- Liver‐Derived Hepatitis C Virus (HCV)‐Specific CD4+ T Cells Recognize Multiple HCV Epitopes and Produce Interferon Gamma (2000) (107)
- Characterization of Hepatitis C Virus Core-Specific Immune Responses Primed in Rhesus Macaques by a Nonclassical ISCOM Vaccine (2001) (105)
- Characterization of antibodies induced by vaccination with Hepatitis C virus envelope glycoproteins (2010) (104)
- Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. (2011) (100)
- Persistence of HCV despite antibodies to both putative envelope glycoproteins (1993) (96)
- Nucleotide sequence of core and envelope genes of the hepatitis C virus genome derived directly from human healthy carriers. (1990) (96)
- Intrahepatic Genetic Inoculation of Hepatitis C Virus RNA Confers Cross-Protective Immunity (2001) (94)
- Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. (2000) (93)
- Folding and dimerization of hepatitis C virus E1 and E2 glycoproteins in stably transfected CHO cells. (2005) (92)
- IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza (2014) (91)
- Characterization of liver T‐cell receptor γδ+ T cells obtained from individuals chronically infected with hepatitis C virus (HCV): Evidence for these T cells playing a role in the liver pathology associated with HCV infections (2001) (89)
- Prevalence of Anti‐HCV Antibody in Blood Donors in the Tokyo Area (1990) (88)
- Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. (2007) (88)
- HCV testing in low-risk population (1990) (83)
- Cationic microparticles are a potent delivery system for a HCV DNA vaccine. (2004) (83)
- 5' end-dependent translation initiation of hepatitis C viral RNA and the presence of putative positive and negative translational control elements within the 5' untranslated region. (1992) (77)
- Hepatitis C Virus and eliminating post-transfusion hepatitis (2000) (77)
- Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus. (2014) (77)
- Prevalence of antibodies to hepatitis C virus among patients with cryptogenic chronic hepatitis and cirrhosis (1992) (76)
- Evaluation of Hepatitis C Virus Glycoprotein E2 for Vaccine Design: an Endoplasmic Reticulum-Retained Recombinant Protein Is Superior to Secreted Recombinant Protein and DNA-Based Vaccine Candidates (2000) (73)
- Hepatitis C viral cDNA clones isolated from a healthy carrier donor implicated in post-transfusion non-A, non-B hepatitis. (1990) (71)
- Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer (2017) (71)
- Effects of interferon treatment on the antiviral T‐cell response in hepatitis C virus genotype 1b‐ and genotype 2c‐infected patients (1997) (68)
- Comprehensive in vitro characterization of PD-L1 small molecule inhibitors (2019) (68)
- Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. (2011) (65)
- Hepatitis C virus envelope glycoprotein E1 originates in the endoplasmic reticulum and requires cytoplasmic processing for presentation by class I MHC molecules. (1999) (63)
- Expression of human CD81 in transgenic mice does not confer susceptibility to hepatitis C virus infection. (2002) (62)
- Induction of Broad CD4+ and CD8+ T-Cell Responses and Cross- Neutralizing Antibodies against Hepatitis C Virus by Vaccination with Th1-Adjuvanted Polypeptides Followed by Defective Alphaviral Particles Expressing Envelope Glycoproteins gpE1 and gpE2 and Nonstructural Proteins 3, 4, and 5 (2008) (60)
- Recombinant Hepatitis C Virus Envelope Glycoprotein Vaccine Elicits Antibodies Targeting Multiple Epitopes on the Envelope Glycoproteins Associated with Broad Cross-Neutralization (2014) (60)
- Progress towards a hepatitis C virus vaccine (2013) (59)
- Human serum leads to differentiation of human hepatoma cells, restoration of very‐low‐density lipoprotein secretion, and a 1000‐fold increase in HCV Japanese fulminant hepatitis type 1 titers (2013) (58)
- INTRAFAMILIAL TRANSMISSION OF HEPATITIS C VIRUS (1989) (56)
- Early Antihepatitis C Virus Response with Second—Generation C200/C22 ELISA (1992) (56)
- Induction in vitro of a primary human antiviral cytotoxic T cell response (1995) (55)
- Risk factors in hepatitis C virus‐infected blood donors (1991) (54)
- Folding of Hepatitis C Virus E1 Glycoprotein in a Cell-Free System (2001) (53)
- Enhanced Sensitivity of a Second Generation ELISA for Antibody to Hepatitis C Virus (1992) (53)
- Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. (2006) (51)
- Strategies and prospects for vaccination against the hepatitis C viruses. (2000) (50)
- Parenterally transmitted non-A, non-B hepatitis: virus-specific antibody response patterns in hepatitis C virus-infected chimpanzees. (1990) (50)
- Variable Patterns of Programmed Death-1 Expression on Fully Functional Memory T Cells after Spontaneous Resolution of Hepatitis C Virus Infection (2008) (48)
- A Refined Model of the HCV NS5A Protein Bound to Daclatasvir Explains Drug-Resistant Mutations and Activity against Divergent Genotypes (2015) (47)
- Group specific sequences and conserved secondary structures at the 3' end of HCV genome and its implication for viral replication (1992) (47)
- Generation of an MHC class II-restricted T cell epitope by extracellular processing of hepatitis delta antigen. (1998) (46)
- A human ether-á-go-go-related (hERG) ion channel atomistic model generated by long supercomputer molecular dynamics simulations and its use in predicting drug cardiotoxicity. (2014) (45)
- Perspectives for a vaccine against hepatitis C virus. (1999) (45)
- Elevated serum alanine aminotransferase levels in blood donors: the contribution of hepatitis C virus. (1991) (44)
- Differential serum levels of eosinophilic eotaxins in primary sclerosing cholangitis, primary biliary cirrhosis, and autoimmune hepatitis. (2014) (42)
- BLOOD SCREENING FOR NON‐A, NON‐B HEPATITIS BY HEPATITIS C VIRUS ANTIBODY ASSAY (1990) (41)
- Reductions in circulating levels of IL-16, IL-7 and VEGF-A in myalgic encephalomyelitis/chronic fatigue syndrome. (2016) (40)
- Hepatitis C virus-specific CD4+ T cell response after liver transplantation occurs early, is multispecific, compartmentalizes to the liver, and does not correlate with recurrent disease. (2001) (39)
- Hepatitis C virus: structure, protein products and processing of the polyprotein precursor. (1994) (37)
- Serum antibodies against the hepatitis C virus E2 protein mediate antibody-dependent cellular cytotoxicity (ADCC). (2005) (36)
- Clinical Medical Research Award. Hepatitis C virus and eliminating post-transfusion hepatitis. (2000) (36)
- Enhanced Activation of Memory, but Not Naïve, B Cells in Chronic Hepatitis C Virus-Infected Patients with Cryoglobulinemia and Advanced Liver Fibrosis (2013) (36)
- Role of hepatitis C virus in non-B chronic liver disease. (1991) (35)
- Identification of the major, parenteral non-A, non-B hepatitis agent (hepatitis C virus) using a recombinant cDNA approach. (1992) (34)
- Peptide Immunogen Mimicry of Putative E1 Glycoprotein-Specific Epitopes in Hepatitis C Virus (1994) (34)
- Disappearance of hepatitis C virus RNA in plasma during interferon alpha-2B treatment in hemophilia patients. (1992) (33)
- Structure and Function of the Hepatitis C Virus Envelope Glycoproteins E1 and E2: Antiviral and Vaccine Targets. (2016) (31)
- Arylacetamide deacetylase: a novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production. (2013) (31)
- Computational Prediction of the Heterodimeric and Higher-Order Structure of gpE1/gpE2 Envelope Glycoproteins Encoded by Hepatitis C Virus (2017) (31)
- Immunodominant CD 4 1 T-Cell Epitope within Nonstructural Protein 3 in Acute Hepatitis C Virus Infection (1997) (31)
- Fabrication of flexible self-standing all-cellulose nanofibrous composite membranes for virus removal. (2016) (31)
- Role of the E2 Hypervariable Region (HVR1) in the Immunogenicity of a Recombinant Hepatitis C Virus Vaccine (2018) (30)
- Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG (2016) (30)
- Characterization of an Immunodominant Antigenic Site on GB Virus C Glycoprotein E2 That Is Involved in Cell Binding (2006) (30)
- Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism (2017) (29)
- Analysis of genomic variability of hepatitis C virus. (1991) (29)
- Detailed Computational Study of the Active Site of the Hepatitis C Viral RNA Polymerase to Aid Novel Drug Design (2013) (28)
- Vaccine adjuvants--understanding molecular mechanisms to improve vaccines. (2014) (27)
- Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells (2020) (27)
- Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes. (2017) (27)
- Hepatitis C virus antibodies in acute icteric and chronic non-A, non-B hepatitis. (1991) (25)
- Minimum data elements for research reports on CFS (2012) (25)
- Hepatitis C Virus Heteroduplex Tracking Assay for Genotype Determination Reveals Diverging Genotype 2 Isolates in Italian Hemodialysis Patients (1998) (25)
- Modeling the human Nav1.5 sodium channel: structural and mechanistic insights of ion permeation and drug blockade (2017) (24)
- Association of cytotoxic T lymphocyte (CTL) escape mutations with persistent hepatitis C virus (HCV) infection. (1995) (24)
- Targeting the Achilles heel of the hepatitis B virus: a review of current treatments against covalently closed circular DNA. (2015) (24)
- An ELISA Based Binding and Competition Method to Rapidly Determine Ligand-receptor Interactions. (2016) (23)
- Effect of Immunosuppression on T-Helper 2 and B-Cell Responses to Influenza Vaccination. (2015) (21)
- Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus (1994) (21)
- Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins (2019) (20)
- HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial (2013) (20)
- Hepatitis C virus markers in patients with long-term biochemical and histological remission of chronic hepatitis. (2008) (19)
- High prevalence of G1 and G2 TT-virus infection in subjects with high and low blood exposure risk: identification of G4 isolates in Italy. (1999) (18)
- No Evidence for XMRV Nucleic Acids, Infectious Virus or Anti-XMRV Antibodies in Canadian Patients with Chronic Fatigue Syndrome (2011) (18)
- Immunization of woodchucks with adjuvanted sHDAg (p24): immune response and outcome following challenge. (2004) (17)
- Quantification of the number of cytotoxic T cells specific for an immunodominant HCV-specific CTL epitope primed by DNA immunization. (2000) (17)
- The Second Canadian Symposium on hepatitis C virus: a call to action. (2013) (16)
- Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants. (2019) (16)
- SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1 (2021) (16)
- Comparison of secretion of a hepatitis C virus glycoprotein in Saccharomyces cerevisiae and Kluyveromyces lactis. (1999) (15)
- Prevalence of circulating antibodies against the hepatitis C virus among different risk groups in Spain (1989) (14)
- A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. (2019) (14)
- Prevention of hepatitis C virus infection using a broad cross‐neutralizing monoclonal antibody (AR4A) and epigallocatechin gallate (2015) (13)
- CD4 T lymphocyte proliferative responses to hepatitis C virus (HCV) antigens in patients coinfected with HCV and human immunodeficiency virus who responded to anti-HCV treatment. (2002) (13)
- Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1. (2020) (13)
- A computational model for overcoming drug resistance using selective dual-inhibitors for aurora kinase A and its T217D variant. (2013) (13)
- Hepatitis C Virus: 30 Years after Its Discovery. (2019) (12)
- Long term treatment of chronic hepatitis C with interferon alfa-2b: disappearance of HCV-RNA in a pilot study of eight haemophilia patients. (1993) (12)
- A Comprehensive Computational Analysis for the Binding Modes of Hepatitis C Virus NS5A Inhibitors: The Question of Symmetry. (2016) (11)
- Isolation of a complementary dna clone derived from a blood borne non a non b viral hepatitis genome (1989) (11)
- Activation of the grp 78 and grp 94 Promoters by Hepatitis C Virus E 2 Envelope Protein (1998) (10)
- Prospects for a hepatitis C virus vaccine. (1999) (10)
- Hepatitis delta (δ) cDNA clones: Undetectable hybridization to nucleic acids from infectious non‐A, non‐B hepatitis materials and hepatitis B DNA (1987) (10)
- Vaccines Against Human Hookworm Disease (2004) (10)
- Effect of IL‐12 on T‐cell immune responses in patients with chronic HCV infection (2000) (10)
- A structure-based computational workflow to predict liability and binding modes of small molecules to hERG (2020) (10)
- A Fibrosis‐Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis (2020) (9)
- Hepatitis C antibody in patients with chronic liver disease and hepatocellular carcinoma (1991) (9)
- Priming of hepatitis C virus–specific cytotoxic t lymphocytes in mice following portal vein injection of a liver‐specific plasmid DNA (2000) (9)
- A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1 (2019) (9)
- Hepatitis C: the next 25years. (2014) (9)
- Prospects for prophylactic and therapeutic hepatitis C virus vaccines. (1995) (9)
- Structure-Function Analysis of Hepatitis C Virus Envelope-CD 81 Binding (2000) (9)
- The viroid-like structure of the hepatitis delta (delta) genome: synthesis of a viral antigen in recombinant bacteria. (1987) (8)
- An inactivated hepatitis C virus vaccine on the horizon? (2013) (8)
- Towards a vaccine for the prevention of hepatitis delta virus superinfection in HBV carriers. (1993) (8)
- The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era. (2014) (8)
- Review article: HCV ? STAT-C era of therapy (2010) (8)
- The effects of using recombinant vaccinia viruses expressing either large or small HDAg to protect woodchuck hepadnavirus carriers from HDV superinfection. (1993) (8)
- Rational Drug Design: One Target, Many Paths to It (2014) (7)
- A computational approach for predicting off-target toxicity of antiviral ribonucleoside analogues to mitochondrial RNA polymerase (2018) (7)
- Use of recombinant HCV antigen in the serodiagnosis of hepatitis C virus infection: Significant improvement in HCV antibody detection as compared with the first generation HCV C100‐3 ELISA and the synthetic peptide EIA tests (1993) (7)
- Application of Polymerase Chain Reaction to Hepatitis C Virus Research and Diagnostics (1992) (6)
- A cDNAfragment ofhepatitis C virus isolated fromanimplicated donorofpost-transfusion non-A, non-Bhepatitis inJapan (1989) (6)
- Distinct Subtypes of Hepatitis C Virus Defined by Antibodies Directed to the Putative Core, NS4, and NS5 Region Polypeptides (1994) (6)
- Structure and Molecular Virology (2013) (5)
- HCV-positive, HIV-1-negative Mothers Transmit HCV (1994) (4)
- The Hepatitis C Virus: Genetic Organization, Persistence, and Vaccine Strategies (1994) (4)
- Lack of antibodies to the envelope glycoproteins of hepatitis C virus in immunoglobulin preparations from screened donors. (1996) (4)
- Sociodemographic risk factors for hepatitis C virus infection in a prospective cohort study of 257 persons in Canada who inject drugs. (2020) (4)
- Allospecific T cell recognition of HLA-A2 antigens: Evidence for group-specific and subgroup-specific epitopes (2004) (4)
- The hepatitis C virus: A new paradigm for the identification and control of infectious disease (2000) (3)
- Hepatitis C virus heteroduplex tracking assay : application to genotype determination, quasispecies analysis, and molecular evolution studies. (1999) (3)
- Hepatitis C virus vaccines (2008) (3)
- Enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies to hepatitis C (non-A, non-B hepatitis) virus (1989) (3)
- 7 Humoral response to hepatitis C virus (2000) (3)
- High prevalence of antibody to hepatitis C virus in patients with hepatocellular carcinoma (HCC) (1989) (2)
- Computational Screening of Molecules Approved in Phase-I Clinical Trials to Identify 3CL Protease Inhibitors to Treat COVID-19 (2020) (2)
- A novel method for detection of IFN-lambda 3 binding to cells for quantifying IFN-lambda receptor expression. (2017) (2)
- The way forward in HCV treatment — finding the right path (2008) (2)
- A196 IDENTIFICATION OF AN IMMUNOSUPPRESSIVE DOMAIN IN HUMAN BETARETROVIRUS (2018) (2)
- 602 THE CANDIDATE HCV E1E2MF59 VACCINE IS SAFE IN CHRONIC HEPATITIS C PATIENTS AND ACCELLERATES THE SECOND PHASE VIRAL DECLINE UPON PRIMARY RESPONSE TO PEG-INTERFERON-2A/RIBAVIRIN THERAPY (2009) (2)
- Rational Drug Design Rational Drug Design: One Target, Many Paths to It (2017) (2)
- Cloning and sequence analysis of hepatitis B virus variants in “non a non B” infections (1990) (2)
- O.015 A phase 1 trial of a novel E1E2/MF59C.1 hepatitis C vaccine candidate in healthy HCV-negative adults (DMID 01-002) (2006) (2)
- Application of Molecular Dynamics Simulations to the Design of Nucleotide Inhibitors Binding to Norovirus Polymerase (2020) (1)
- Chimp Virus Makes a Savvy Vaccine Vector (2012) (1)
- Three isn't the magic number (2013) (1)
- Seroepidemiology of Hepatitis C Among Drug Users at a Detoxification Center in Southeast China (2020) (1)
- Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19 (2021) (1)
- Progress toward approval of an HCV vaccine. (2018) (1)
- Towards the Control of Hepatitis C (2016) (1)
- Hepatitis C Virus-specific Cytotoxic T Lymphocytes Restricted by HLA-A2 are Present in the Peripheral Blood of Patients with Chronic Hepatitis C (1994) (1)
- Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. (2021) (1)
- HCV deffection in “autonimine” chronic active hepatitis (1990) (1)
- NANBV diagnostics: polynucleotides, suitable for screening for hepatitis C virus (1990) (1)
- Computational determination of toxicity risks associated with a selection of approved drugs having demonstrated activity against COVID-19 (2021) (1)
- Rabbit-derived anti-HD antibodies for HDAg immunoblotting. (1991) (1)
- a Cohort of Persons with Chronic Infection in Infection: Breadth and Specificity of Responses Liver-Derived CTL in Hepatitis C Virus (1998) (0)
- The Discovery of the Hepatitis C Virus (2019) (0)
- Rabbit-derived anti-HD antibodies for HDAg immunoblotting. (1993) (0)
- Diagnosis and vaccines of hepatitis delta their preparation and use. (1987) (0)
- Role of the E2 hypervariable region (HVR1) in the immunogenicity of a 1 recombinant HCV vaccine (2018) (0)
- Isolates d'HCV (1990) (0)
- Glycogen synthase kinase 3β inhibitors prevent hepatitis C virus release/assembly through perturbation of lipid metabolism (2017) (0)
- Intrahepatic HCV-Specific CD4+ T cells in chronic HCV-infection are multispecific and produce γ-IFN (2000) (0)
- Why Did The Discovery of Hepatitis C Virus Win The Nobel Prize? (2020) (0)
- A novel method for the detection of IFN-lambda 3 binding to cells to quantify IFN-lambda receptor expression on epithelial and immune cell subsets (2017) (0)
- NANBV diagnostics: for the investigation on hepatitis c usable polynucleotides (1991) (0)
- Vaccination Against the Hepatitis C Virus (2009) (0)
- Anti-hepatitis C virus in nonAnonB patients responding and non-responding to alpha-2A interferon (1989) (0)
- Three-Dimensional Reconstruction of the Hepatitis C Virus Envelope Glycoprotein E1E2 Heterodimer by Electron Microscopic Analysis (2022) (0)
- Sektretierter E1 / E2 complex hepatitis C virus obtained from C-terminally truncated E1 and E2 polypeptides (1995) (0)
- Hepatitis C virus (HCV)-specific CD8+ T cells in patients with recurrent HCV-infection after liver transplantation (OLTx) (2001) (0)
- HLA-Class I Antigen Recognition by EB Virus-Specific and Allo-Specific Cytotoxic T Cells (1985) (0)
- The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin (2009) (0)
- Efficacy of alfa-interferon to prevent chronicity in patients with acute postransfusion non-A non-B hepatitis: A randimized, controlled trial (1989) (0)
- Hepatitis C Virus Hybridizing Polynucleotides, Kits Containing and Their Uses (2000) (0)
- The secreted E1 / E2 complex of the Hepatitis C virus, the truncated from C-terminal polypeptides is obtained E1 and E2 (1995) (0)
- Down-regulation of CCR5 expression by hepatitis C virus (2003) (0)
- Rabbit-derived anti- antibodies for (1991) (0)
- Decision letter: An ultralong CDRH2 in HCV neutralizing antibody demonstrates structural plasticity of antibodies against E2 glycoprotein (2020) (0)
- Only a strong, multispecific, and longlasting CD4+ T cell response is associated with viral elimination in patients with recurrent HCV-infection after OLTx (2001) (0)
- Useofa Signature Nucleotide Sequence ofHepatitis C Virusfor Detection ofViral RNA inHumanSerumandPlasma (1991) (0)
- This information is current as Presentation by Class I MHC Molecules Requires Cytoplasmic Processing for andOriginates in the Endoplasmic Reticulum Hepatitis C Virus Envelope Glycoprotein E 1 (1998) (0)
- Combinations of antigens Hepatitis C virus (HCV) for use in immunoassays for anti-HCV antibodies. (1991) (0)
- Hepatitis C Virus Envelope Glycoprotein E 1 Originates in the Endoplasmic Reticulum and Requires Cytoplasmic Processing for Presentation by Class I MHC Molecules 1 (1998) (0)
- HCV isolate J-1 (1990) (0)
- Polynucleotides and methods useful in screening for hepatitis C virus (1991) (0)
- IFN-lambda 3 directly induces antiviral responses in human B and T cells leading to inhibition of HIV-1 infection of CD4+ T cells (2020) (0)
- A method for culturing HCV in cell lines of B or T lymphocytes (1990) (0)
- 26 – Hepatitis C Vaccines (2018) (0)
- HBV / HCV virus Similar Particle (2000) (0)
- Atomistic Computational Models to Predict Drug-Mediated Cardiotoxicity (2019) (0)
- Characterization ofHepatitis C VirusEnvelope Glycoprotein Complexes Expressed byRecombinant Vaccinia Viruses (1993) (0)
- Human Specific CD4+ T Cell Response to Hepatitis Delta Virus (1996) (0)
- List of SYBR RT-qPCR primer sequences. (2020) (0)
- NANBV diagnostics: screening for hepatitis C virus useful polynucleotides (1993) (0)
- Composition of several immunoreactive Hepatitis C virus polypeptides (1992) (0)
- Diagnostic and vaccine for hepatitis delta (1995) (0)
- Diagnostic agent and vaccine for hepatitis delta (1995) (0)
- Binding of HCV E2 to CD81 enhances surface expression of HLA-E (2003) (0)
- HCV polynucleotides include those kits and their use (2000) (0)
- DNA-Based Vaccine Candidates Secreted Recombinant Protein and Recombinant Protein Is Superior to Endoplasmic Reticulum-Retained Glycoprotein E 2 for Vaccine Design : an Evaluation of Hepatitis C Virus (2000) (0)
- NANB diagnostik i screening of viral hepatitis, c anvaendbara polynukleotider (1993) (0)
- A process for the preparation of HCV polypeptides (1998) (0)
- Contributors (2008) (0)
- Methods and compositions for controlling the translation of HCV proteins (1993) (0)
- Antigen Epitope by Extracellular Processing of Hepatitis Generation of an MHC Class II-Restricted T Cell (1998) (0)
- Determination of Pharmacokinetics and Pharmacodynamics of Lamivudine After Highdoses in Duck Hepatitis B Virus-Infected Pekin Ducks (2018) (0)
- Compositions immunoreactive with hepatitis C virus polypeptide (1992) (0)
- Process for the preparation of HCV polypeptides, and the recombinant vectors used in the method (1998) (0)
- Hepatitis C vaccines to prevent liver cancer (2004) (0)
- Combinations c virus antigens Hepatitis (HCV) for use in immunoassays for anti-HCV antibodies. (1991) (0)
- Response of T cells from HCV reinfected grafts after LTX resembles that of T cells from peripheral blood in acute hepatitis C (1998) (0)
- Immunogenic composition comprising a SARS coronavirus spicular protein (2004) (0)
- Diagnostics du virus non a, non b: polynucleotides utiles dans la detection du virus de l'hepatite c (1991) (0)
- Diagnoses of hepatitis non-A, non-B (NANBV) polynucleotides useful for screening the Hepatitis C virus. (1991) (0)
- Cross-genotype hepatitis C virus (HCV)-specific cytotoxic T lymphocyte (CTL) activity in the liver in chronic hepatitis C (1995) (0)
- Hepatitis C virus :clinical significance of anti-HCV and HCV-RNA and characterization of an Italian isolate (1989) (0)
- Protease Hepatitis C virus. (1991) (0)
- Modified small irns molecules and methods for their application (2003) (0)
- E1E2 protein adjuvanted with MF59 HCV more alphavirus vector encoding E1E2 HCV specific T cells to induce HCV (2007) (0)
- Su.64. Enhancement of Cd8+ T-Cell Responses to Hepatitis C Viral E1e2 Glycoprotein Using Defective Alphavirus Replicon Particle As a Delivery Vector (2006) (0)
- 48 – Hepatitis C vaccines (2012) (0)
- UvA-DARE ( Digital Academic Repository ) Adhesion molecules in atopic dermatitis : Patch tests elicited by house dust mite (2017) (0)
This paper list is powered by the following services:
Other Resources About Michael Houghton
What Schools Are Affiliated With Michael Houghton ?
Michael Houghton is affiliated with the following schools:
